despite the partly insufficient therapy results after unique radiotherapy and polychemotherapy , the combined method has largely contributed to achieve after eight years the total survival rates of 76 % for cb/cc nhl ( n = 123 ) and of 55 % for the highly malignant immunoblastic nhl ( n = 57 ) , centroblastic nhl ( n = 35 ) and nhl with uncertain classification , whereas the cc-nhl ( n = 36 ) hitherto has a relatively unfavorable prognosis with only 29 % .
C0079746
immunoblastic nhl
C0024305
nhl